Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Receives Average Rating of "Hold" from Brokerages

Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) has been given a consensus recommendation of "Hold" by the five analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $29.6667.Get Eton Pharmaceuticals alerts:A number of analysts have recently commented on ETON shares. Zacks Research lowered Eton Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Thursday, November 13th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Eton Pharmaceuticals in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Eton Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, December 13th.Check Out Our Latest Analysis on ETONInstitutional Trading of Eton PharmaceuticalsA number of institutional investors and hedge funds have recently bought and sold shares of the stock. State of Alaska Department of Revenue acquired a new position in Eton Pharmaceuticals during the 3rd quarter worth about $30,000. Ameritas Investment Partners Inc. bought a new position in shares of Eton Pharmaceuticals during the second quarter worth about $37,000. Quarry LP bought a new position in shares of Eton Pharmaceuticals during the third quarter worth about $37,000. Legal & General Group Plc acquired a new position in shares of Eton Pharmaceuticals in the second quarter worth approximately $41,000. Finally, AlphaQuest LLC bought a new stake in Eton Pharmaceuticals in the first quarter valued at approximately $53,000. 27.86% of the stock is currently owned by institutional investors and hedge funds. Eton Pharmaceuticals Stock PerformanceNASDAQ ETON opened at $16.57 on Tuesday. The firm's fifty day moving average price is $17.21 and its two-hundred day moving average price is $16.76. The stock has a market cap of $444.41 million, a PE ratio of -66.28 and a beta of 1.17. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.25 and a current ratio of 1.63. Eton Pharmaceuticals has a fifty-two week low of $11.09 and a fifty-two week high of $23.00. Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.20). The firm had revenue of $22.46 million for the quarter, compared to analyst estimates of $20.47 million. Eton Pharmaceuticals had a negative net margin of 9.50% and a negative return on equity of 11.32%. On average, equities analysts expect that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year. Eton Pharmaceuticals Company Profile (Get Free Report)Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings. The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.Featured ArticlesFive stocks we like better than Eton PharmaceuticalsDo not delete, read immediatelyINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffCan Any Expenses Be Deducted From Capital Gains Tax?Buffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyThe Last Gold Bull Market This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Eton Pharmaceuticals Right Now?Before you consider Eton Pharmaceuticals, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.While Eton Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here